Drugs / DYN101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04743557 | Jan 2024 → Sep 2025 | centronuclear myopathy | Dynacure | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04033159 | Jan 2020 → Jun 2022 | centronuclear myopathy | Dynacure | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DYN101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04033159 ↗ |
| Modality | Antisense oligonucleotide | “DYN101 is a synthetically manufactured constrained ethyl gapmer antisense oligonucleotide (ASO)” NCT04033159 ↗ |
| Route | Intravenous | “for intravenous (IV) administration” NCT04033159 ↗ |
| Target | DNM2 | “DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA” NCT04033159 ↗ |